Navigation Links
Pfenex Announces Strategic Collaboration With MedImmune for the Use of Pfenex Expression Technology™
Date:5/10/2011

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology™ platform, announced today a three year strategic collaboration with MedImmune LLC, the global biologics business of AstraZeneca. The agreement provides MedImmune with non-exclusive access to Pfenex Expression Technology and scientific resources for the development of bioprocesses for human therapeutic proteins and vaccines.

Pfenex Inc. will engineer production strains and develop early production processes for MedImmune's proprietary molecules. A Joint Steering Committee will be established to oversee the collaboration and facilitate the decision-making process. This collaboration provides MedImmune with access to an industry-leading expression platform and process development team that will enable preclinical and clinical development for these molecules to progress quickly and efficiently. MedImmune will provide annual technology access fees, FTE resource funding and will also have pre-agreed commercial license terms.

"This partnership with MedImmune will facilitate speed and reliability in the development of protein therapeutics and vaccines to serve unmet medical needs," said Dr. Bertrand Liang, CEO of Pfenex Inc. "Integrating our efforts early will allow for the rapid progression of early stage candidate molecules through discovery and development."

"We are very excited to initiate this collaboration with Pfenex" said Dr. Gail Wasserman, Senior Vice President of Biopharmaceutical Development at MedImmune. "Their scientific approach to strain development and protein expression is robust and aligned with the way we work at MedImmune.  Working collaboratively with Pfenex by harnessing their novel platform will play an important role in helping accelerate some of our early pipeline programs."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals.  For more information please visit www.pfenex.com

About MedImmune, LLC

MedImmune, the global biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
2. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
3. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
4. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
5. Insmed Announces First Quarter 2011 Financial Results
6. Intercell AG Announces Q1 2011 Results and Updates on R&D Progress
7. Mindray Announces First Quarter 2011 Financial Results
8. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
9. Rosetta Genomics Announces Issuance of Additional U.S. Patent
10. Frantz Medical Group Announces the Promotion of Stephanie Harrington to Chief Operating Officer
11. Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
Breaking Medicine Technology:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):